Corline Biomedical AB (CLBIO)

Currency in SEK
17.95
+0.20(+1.13%)
Real-time Data·
CLBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.5018.35
52 wk Range
11.2527.20
Key Statistics
Prev. Close
17.75
Open
17.7
Day's Range
16.5-18.35
52 wk Range
11.25-27.2
Volume
4.92K
Average Volume (3m)
13.08K
1-Year Change
34.9624%
Book Value / Share
3.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Corline Biomedical AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 08, 2026
EPS / Forecast
-0.10 / --
Revenue / Forecast
4.3M / 9.9M
EPS Revisions
Last 90 days

CLBIO Income Statement

Compare CLBIO to Peers and Sector

Metrics to compare
CLBIO
Peers
Sector
Relationship
P/E Ratio
−32.8x−21.6x−0.4x
PEG Ratio
−0.68−0.850.00
Price/Book
4.6x1.3x2.6x
Price / LTM Sales
43.5x0.6x3.0x
Upside (Analyst Target)
63.4%0.0%50.7%
Fair Value Upside
Unlock43.0%6.5%Unlock

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.

Employees
13
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
7.41M28.34%136.63M
Public Companies & Retail Investors
18.73M71.66%345.53M
Total
26.13M100.00%482.16M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Eccenovo Ab7.06%1,843,94334,021
Eiffel Investment Group S.A.S.4.80%1,253,71723,131

FAQ

What Is the Corline Biomedical AB (CLBIO) Stock Price Today?

The Corline Biomedical AB stock price today is 17.95 SEK.

What Stock Exchange Does Corline Biomedical AB Trade On?

Corline Biomedical AB is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Corline Biomedical AB?

The stock symbol for Corline Biomedical AB is "CLBIO."

What Is the Corline Biomedical AB Market Cap?

As of today, Corline Biomedical AB market cap is 469.09M SEK.

What Is Corline Biomedical AB's Earnings Per Share (TTM)?

The Corline Biomedical AB EPS (TTM) is -0.57.

When Is the Next Corline Biomedical AB Earnings Date?

Corline Biomedical AB will release its next earnings report on Aug 21, 2026.

From a Technical Analysis Perspective, Is CLBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Corline Biomedical AB Stock Split?

Corline Biomedical AB has split 2 times.

How Many Employees Does Corline Biomedical AB Have?

Corline Biomedical AB has 13 employees.

What is the current trading status of Corline Biomedical AB (CLBIO)?

As of Jul 03, 2026, Corline Biomedical AB (CLBIO) is trading at a price of 17.95 SEK, with a previous close of 17.75 SEK. The stock has fluctuated within a day range of 16.50 SEK to 18.35 SEK, while its 52-week range spans from 11.25 SEK to 27.20 SEK.

What Is Corline Biomedical AB (CLBIO) Price Target According to Analysts?

The average 12-month price target for Corline Biomedical AB is 29.00 SEK, with a high estimate of 29 SEK and a low estimate of 29 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +61.56% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.